PaxMedica (MEX:PXMD) Beginning Cash Position: MXN6.38 Mil (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PXMD PaxMedica Inc MEX:PXMD
20 GF Score
Price MXN15.69
View Full Analysis

What is PaxMedica Beginning Cash Position?

PaxMedica MEX:PXMD 20 Beginning Cash Position is MXN6.38 Mil as of Sep. 2024. GuruFocus rates MEX:PXMD with a GF Score™ of 20/100.

PaxMedica's Beginning Cash Position for the quarter that ended in Sep. 2024 was MXN6.38 Mil.

PaxMedica's quarterly Beginning Cash Position declined from Mar. 2024 (MXN78.17 Mil) to Jun. 2024 (MXN29.79 Mil) and declined from Jun. 2024 (MXN29.79 Mil) to Sep. 2024 (MXN6.38 Mil).

PaxMedica's annual Beginning Cash Position declined from Dec. 2021 (MXN23.06 Mil) to Dec. 2022 (MXN8.66 Mil) but then increased from Dec. 2022 (MXN8.66 Mil) to Dec. 2023 (MXN32.30 Mil).

PaxMedica Beginning Cash Position Related Terms

PaxMedica Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for PaxMedica's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PaxMedica Beginning Cash Position Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial 0.17 0.50 23.06 8.66 32.30

PaxMedica Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.48 19.57 78.17 29.79 6.38
MEX:PXMD
20GF Score
PaxMedica Inc MEX:PXMD
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PaxMedica Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of MXN6.38 Mil mean?
PaxMedica (MEX:PXMD) has a Beginning Cash Position of MXN6.38 Mil as of Sep. 2024. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PaxMedica and its competitors.
Is PaxMedica's Beginning Cash Position too high?
PaxMedica's current Beginning Cash Position is MXN6.38 Mil. Overall, PaxMedica has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does PaxMedica's Beginning Cash Position compare to BTAX and NBIO?
PaxMedica's Beginning Cash Position of MXN6.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PaxMedica and its competitors. PaxMedica's current Beginning Cash Position is MXN6.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (MEX:PXMD) has a current Beginning Cash Position of MXN6.38 Mil. The current Beginning Cash Position is MXN6.38 Mil. PaxMedica's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PaxMedica (MEX:PXMD), the current Beginning Cash Position is MXN6.38 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
20GF Score

Get the complete analysis for MEX:PXMD

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.69
Price